TERRIFRAC SOLO 600 UG/2

About

TERRIFRAC SOLO 600 UG/2 contains Teriparatide, a recombinant human parathyroid hormone (PTH) analog. It is primarily used in the treatment of severe osteoporosis in postmenopausal women and men at high risk of fracture. Unlike antiresorptive agents that slow bone breakdown, Teriparatide acts as an anabolic agent, stimulating new bone formation. It achieves this by intermittently activating osteoblasts, the cells responsible for building bone matrix.

This unique mechanism leads to significant increases in bone mineral density and a reduction in the risk of vertebral and non-vertebral fractures. Its administration is typically subcutaneous, and treatment duration is usually limited to two years, providing a targeted approach to improve bone strength and reduce the incidence of fragility fractures.

Uses

• Treatment of osteoporosis in postmenopausal women.
• Management of osteoporosis in men at high risk of fracture.
• Treatment of glucocorticoid-induced osteoporosis.
• Increases bone mineral density and reduces fracture risk.

Directions For Use

Administer subcutaneously once daily, preferably in the thigh or abdominal wall, as directed by your physician.

Benefits

• Stimulates new bone formation.
• Significantly increases bone mineral density.
• Reduces the risk of vertebral fractures.
• Reduces the risk of non-vertebral fractures.
• Effective in severe osteoporosis.
• Offers an anabolic approach to bone health.

Side Effects

• Nausea.
• Leg cramps.
• Dizziness.
• Headache.
• Joint pain (arthralgia).
• Injection site reactions (pain, swelling, bruising).
• Orthostatic hypotension (dizziness upon standing).
• Hypercalcemia (elevated calcium levels).
• Hyperuricemia (elevated uric acid levels).
• Palpitations.
• Asthenia (weakness).
• Risk of osteosarcoma (rare, observed in animal studies).

Safety Measures

• Alcohol - Limit alcohol intake as it can contribute to bone loss and may exacerbate dizziness or orthostatic hypotension.
• Pregnancy - TERRIFRAC is contraindicated in pregnancy. Women of childbearing potential should use effective contraception during treatment.
• Breastfeeding - It is not known if Teriparatide is excreted in human milk. Breastfeeding is not recommended during treatment.
• Liver - No specific dose adjustment is typically required for liver impairment, but caution is advised.
• Kidney - Use with caution in patients with moderate renal impairment. It is contraindicated in severe renal impairment.
• Lung - No specific contraindications related to lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.